166 related articles for article (PubMed ID: 28642104)
1. Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
Zhang X; Cai C; Winters M; Wells M; Wall M; Lanter J; Sui Z; Ma J; Novack A; Nashashibi I; Wang Y; Yan W; Suckow A; Hua H; Bell A; Haug P; Clapper W; Jenkinson C; Gunnet J; Leonard J; Murray WV
Bioorg Med Chem Lett; 2017 Aug; 27(15):3272-3278. PubMed ID: 28642104
[TBL] [Abstract][Full Text] [Related]
2. Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist.
Sparks SM; Aquino C; Banker P; Collins JL; Cowan D; Diaz C; Dock ST; Hertzog DL; Liang X; Swiger ED; Yuen J; Chen G; Jayawickreme C; Moncol D; Nystrom C; Rash V; Rimele T; Roller S; Ross S
Bioorg Med Chem Lett; 2017 Mar; 27(5):1278-1283. PubMed ID: 28148462
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
[TBL] [Abstract][Full Text] [Related]
4. GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.
Carullo G; Mazzotta S; Vega-Holm M; Iglesias-Guerra F; Vega-Pérez JM; Aiello F; Brizzi A
J Med Chem; 2021 Apr; 64(8):4312-4332. PubMed ID: 33843223
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists.
Li Z; Liu C; Xu X; Shi W; Li H; Dai Y; Cai X; Huang W; Qian H
Bioorg Chem; 2018 Feb; 76():303-313. PubMed ID: 29223807
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
[TBL] [Abstract][Full Text] [Related]
8. Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.
Ji G; Guo Q; Xue Q; Kong R; Wang S; Lei K; Liu R; Wang X
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833999
[TBL] [Abstract][Full Text] [Related]
9. GPR120 agonism as a countermeasure against metabolic diseases.
Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
Drug Discov Today; 2014 May; 19(5):670-9. PubMed ID: 24315954
[TBL] [Abstract][Full Text] [Related]
10. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
[TBL] [Abstract][Full Text] [Related]
11. Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.
Lombardo M; Bender K; London C; Plotkin MA; Kirkland M; Mane J; Pachanski M; Geissler W; Cummings J; Habulihaz B; Akiyama TE; Di Salvo J; Madeira M; Pols J; Powles MA; Finley MF; Johnson E; Roussel T; Uebele VN; Crespo A; Leung D; Alleyne C; Trusca D; Lei Y; Howard AD; Ujjainwalla F; Tata JR; Sinz CJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5724-5728. PubMed ID: 27815121
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent and selective GPR120 agonist.
Shimpukade B; Hudson BD; Hovgaard CK; Milligan G; Ulven T
J Med Chem; 2012 May; 55(9):4511-5. PubMed ID: 22519963
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids.
Colín-Lozano B; Estrada-Soto S; Chávez-Silva F; Gutiérrez-Hernández A; Cerón-Romero L; Giacoman-Martínez A; Almanza-Pérez JC; Hernández-Núñez E; Wang Z; Xie X; Cappiello M; Balestri F; Mura U; Navarrete-Vazquez G
Molecules; 2018 Feb; 23(2):. PubMed ID: 29415496
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
19. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT
Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
